Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary & Life Sciences, Sir Graeme Davies Building, University of Glasgow, Glasgow, UK.
Eur J Immunol. 2018 Jan;48(1):32-38. doi: 10.1002/eji.201746938. Epub 2017 Dec 14.
Advances in targeted immune therapeutics have profoundly improved clinical outcomes for patients with inflammatory arthropathies particularly rheumatoid arthritis. The landscape of disease that is observed and the treatment outcomes desired for the future have also progressed. As such there is an increasing move away from traditional models of end-stage, chronic disease with recognition of the need to consider the earliest phases of pathogenesis as a target for treatment leading to resolution and/or cure. In order to continue the discovery process and enhance our understanding of disease and treatment, we therefore need to continuously revisit the animal models we employ and assess their relevance and utility in the light of contemporary therapeutic goals. In this review, we highlight the areas where we consider new developments in animal models and their application are most required. Thus, we have contextualised the relevant mouse models and their use within the current concepts of human inflammatory arthritis pathogenesis and highlight areas of need.
靶向免疫治疗的进展极大地改善了炎症性关节炎患者(尤其是类风湿关节炎患者)的临床预后。人们观察到的疾病模式和未来期望的治疗结果也在不断发展。因此,人们越来越远离传统的终末期慢性疾病模式,认识到需要将发病的早期阶段作为治疗靶点,以实现缓解和/或治愈。为了继续发现过程并增强我们对疾病和治疗的理解,因此我们需要不断重新审视我们使用的动物模型,并根据当代治疗目标评估其相关性和实用性。在这篇综述中,我们强调了我们认为最需要新的动物模型发展及其应用的领域。因此,我们将相关的小鼠模型及其在当前人类炎症性关节炎发病机制概念中的应用进行了背景化处理,并强调了需要解决的领域。